ROXADUSTAT film coated tablets (Evrenzo®▼)
for treating symptomatic anaemia in chronic kidney disease

The Pan Mersey Area Prescribing Committee recommends the prescribing of ROXADUSTAT film coated tablets (Evrenzo®▼), by specialists only, for treating symptomatic anaemia in chronic kidney disease in accordance with NICE TA807.

RED

NICE technology appraisal (TA) 807 (13 July 2022) recommends roxadustat as an option for treating symptomatic anaemia associated with chronic kidney disease (CKD) in adults only if:

>   they have stage 3 to 5 CKD with no iron deficiency and
>   they are not on dialysis at the start of treatment and
>   the company provides roxadustat according to the commercial arrangement

Prescribing and monitoring must be retained by a specialist in the management of anaemia in chronic kidney disease (CKD).

Costing information

Based on the NICE Resource Impact Template, NICE estimates that the cost of implementing NICE TA807 is £3,000 per 100,000 population in 2022/23, rising to £8,000 per 100,000 population by 2024/25 when it is assumed that steady state has been reached. This is based on the NHS list price and includes any additional administration costs. The resource impact will be less once the PAS discount is applied.

References
1. National Institute for Health and Care Excellence. Technology Appraisal 807; Roxadustat for treatment of symptomatic anaemia in chronic kidney disease 13 July 2022. Accessed online 31 August 2022

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.

APC board date: 28 Sep 2022   Prescribing policy statement
Review date: Sep 2024 (or earlier if there is significant new evidence relating to this recommendation)   Version: 2.0
APC administration provided by Midlands and Lancashire Commissioning Support Unit